drugset / Trial / NCT05880394
Study of Dotatate Imaging in Breast Cancer
NaSingle-groupOpen-labelDiagnostic
Summary
This will be a Phase 2 clinical trial to assess somatostatin receptor (SSTR) expression in Stage IV estrogen receptor positive (ER+) breast cancer using Gallium-68 DOTATATE or Copper-64 DOTATATE PET/CT.
Timeline
- Start
- 2023-01-10
- Primary completion
- 2024-07-31
- Completion
- 2024-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 68Ga-DOTATATE | Diagnostic / imaging agent | — | — |
| Subject | COPPER OXODOTREOTIDE | Peptide | — | — |